Investors

Corporate Overview

BioSpecifics Technologies Corp. is a biopharmaceutical company that is the originator of collagenase-based therapies with injectable collagenase for twelve clinical indications to date. Injectable collagenase (collagenase clostridium histolyticum or CCH) is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren’s contracture and for Peyronie's disease in Canada, Europe and Australia. Endo has engaged partners outside of the U.S. to commercialize Dupuytren’s contracture and Peyronie’s disease.

Latest News